Larson Financial Group LLC Has $4.68 Million Stake in Boston Scientific Co. (NYSE:BSX)

Larson Financial Group LLC grew its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 9.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 52,409 shares of the medical equipment provider's stock after purchasing an additional 4,599 shares during the quarter. Larson Financial Group LLC's holdings in Boston Scientific were worth $4,681,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. TFC Financial Management Inc. grew its holdings in Boston Scientific by 308.8% in the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 210 shares during the last quarter. Dunhill Financial LLC boosted its position in shares of Boston Scientific by 86.4% in the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 152 shares during the period. Global Wealth Strategies & Associates grew its stake in shares of Boston Scientific by 423.7% in the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 250 shares during the last quarter. West Oak Capital LLC bought a new position in Boston Scientific during the fourth quarter worth $29,000. Finally, Capital Performance Advisors LLP acquired a new position in Boston Scientific during the 3rd quarter valued at $30,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Price Performance

Shares of BSX stock traded up $0.90 during trading hours on Wednesday, reaching $96.42. 8,790,888 shares of the company were exchanged, compared to its average volume of 5,775,970. Boston Scientific Co. has a fifty-two week low of $65.52 and a fifty-two week high of $107.17. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. The stock's fifty day moving average is $100.66 and its two-hundred day moving average is $91.49. The company has a market cap of $142.29 billion, a price-to-earnings ratio of 77.14, a P/E/G ratio of 2.79 and a beta of 0.77.

Remove Ads

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Sell-side analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Insider Activity

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the sale, the executive vice president now directly owns 5,502 shares in the company, valued at $560,103.60. This represents a 75.88 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of Boston Scientific stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $104.25, for a total value of $487,368.75. Following the transaction, the executive vice president now owns 28,454 shares in the company, valued at $2,966,329.50. This trade represents a 14.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 137,302 shares of company stock valued at $14,319,269 in the last ninety days. 0.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

BSX has been the topic of several research analyst reports. StockNews.com lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday. Raymond James lifted their target price on Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a research report on Thursday, February 6th. JPMorgan Chase & Co. upped their price target on Boston Scientific from $100.00 to $110.00 and gave the company an "overweight" rating in a report on Monday, December 16th. Wells Fargo & Company lifted their price objective on Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a report on Thursday, February 6th. Finally, Piper Sandler upped their target price on Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Two investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of "Moderate Buy" and a consensus price target of $108.91.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.